| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.2 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.034 | 0.2 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.2 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.3 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.06 | 0.3 |